Clinical trials: Obstructive Pulmonary Disease
COPD Exacerbation
Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide. In contrast to other chronic diseases, COPD is increasing in prevalence and is projected to be the third-leading cause of…
- Trial name
- COPD-ST2OP (NCT03615040)
- Testing
- MSTT1041A
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- University of Leicester
Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation
Effect of Roflumilast at Acute Exacerbations of Chronic Obstructive Pulmonary Disease
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- TREAT (NCT01473758)
- Testing
- Roflumilast
- Where
- 2 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
COPD
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
This study will investigate whether switching symptomatic COPD patients from a fixed-dose combination of salmeterol/fluticasone 50/500 µg b.i.d. to a fixed dose combination of QVA149 110/50 µg o.d.
- Trial name
- FLASH (NCT02516592)
- Testing
- QVA149 110/50 micrograms, Salmeterol/fluticasone 50/500 microgrammes
- Where
- 64 sites in Australia, Egypt and 9 more
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso
The investigators' hypothesis is that pretreating patients with COPD with inhaled treprostinil prior to pulmonary rehabilitation sessions will result in improved exercise tolerance during sessions.
- Trial name
- NCT02178566
- Testing
- Inhaled Treprostinil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Inova Health Care Services
Pulmonary Disease, Chronic Obstructive
Tiotropium / Respimat One-Year Study
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
- Trial name
- NCT00168831
- Testing
- Tiotropium Inhalation Solution
- Where
- 76 sites in United States, Australia and 13 more
- Volunteers
- 1,007 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive, Emphysema
Sildenafil for Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine if sildenafil improves the exercise capacity and lung function of patients with chronic obstructive pulmonary disease.
- Trial name
- NCT00104637
- Testing
- sildenafil citrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kawut, Steven, MD
Pulmonary Disease, Chronic Obstructive
SATisfaction and Adherence to COPD Treatment
The present study will explore the patients satisfaction to COPD medical treatment (i.e. pharmacological and not pharmacological treatment) in a clinical real-world setting and how the satisfaction for medical treatment is…
- Trial name
- NCT02689492
- Where
- 20 sites in Italy
- Volunteers
- 401 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Diseases, Chronic Airways Limitation
Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
Some patients with chronic obstructive pulmonary diseases (COPD) have large number of specific white blood cells called eosinophils in their airways.
- Conditions
- Chronic Obstructive Pulmonary Diseases, Chronic Airways Limitation, Bronchitis
- Trial name
- NCT01463644
- Testing
- Mepolizumab
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- McMaster University
Pulmonary Disease, Chronic Obstructive
A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate in patients with Chronic Obstructive Pulmonary Disease (COPD) if Advair DISKUS™ 250/50mcg BID modifies arterial stiffness which is a measure associated with risk of heart disease.
- Trial name
- NCT00857766
- Testing
- ADVAIR DISKUS™ 250/50mcg
- Where
- 24 sites in United States
- Volunteers
- 249 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Safety and Dose-Range of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (MK-7123-012)
This is a two-part study conducted at multiple centers, of navarixin (SCH 527123, MK-7123) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00441701
- Testing
- Navarixin 1 mg, Navarixin 10 mg, Rescue medication
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Cachexia
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.
- Trial name
- NCT00698828
- Testing
- SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 227 people
- Sponsor
- Daiichi Sankyo
Central Serous Chorioretinopathy
Eplerenone for the Treatment of Central Serous Chorioretinopathy
To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .
- Trial name
- NCT01990677
- Testing
- 25mg Eplerenone
- Where
- 10 sites in United States
- Volunteers
- 108 people
- Sponsor
- Wills Eye
Chronic Obstructive Pulmonary Disease
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
The purpose of this study is to determine if ensifentrine is safe and effective for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT04542057
- Testing
- Ensifentrine
- Where
- 130 sites in United States, Belgium and 8 more
- Volunteers
- 790 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Chronic Obstructive Pulmonary Disease
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to evaluate, after 1 week of dosing, the efficacy and safety of PT003 compared with its individual components (PT001 and PT005), placebo and two active comparators to demonstrate superiority of the…
- Trial name
- NCT01085045
- Testing
- PT003 MDI, PT005 MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®)
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 118 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD, Self-management Behaviors
Comprehensive Self-management Support for COPD Patients
The study team will adapt and expand an effective model of asthma self-management support for patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- SAMBA COPD (NCT04533412)
- Testing
- Self-management barrier support, Basic COPD Education
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Asthma
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of…
- Trial name
- NCT02322775
- Testing
- Benralizumab
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Cancer, Congestive Heart Failure
Outlook Quality of Life Intervention
The purpose of this study is to determine whether discussions of life story, forgiveness, and future goals improve quality of life for patients with serious illness.
- Conditions
- Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT00784095
- Testing
- Life completion and preparation, Attention Control
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- VA Office of Research and Development
COPD, Chronic Obstructive Pulmonary Disease
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the dose-response of different doses of CHF 5259 pMDI on lung function and other clinical outcomes, to identify the optimal dose(s) in terms of benefit/ risk ratio for further development…
- Trial name
- GLIMMER (NCT03084796)
- Testing
- CHF 5259, Tiotropium Bromide 18 µg Inhalation Capsule
- Where
- 112 sites in United States
- Volunteers
- 733 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-centered, randomized, placebo-controlled, double-blind, parallel group, trial evaluating 2 doses of mepolizumab against placebo given every 4 weeks through subcutaneous (SC) injection.
- Trial name
- NCT02105961
- Testing
- Mepolizumab
- Where
- 169 sites in United States, Argentina and 13 more
- Volunteers
- 674 people
- Sponsor
- GlaxoSmithKline
Asthma
A Multifaceted Prompting Intervention for Urban Children With Asthma
The overall goal of this project is to evaluate whether a multifaceted prompting intervention, administered in the urban primary care office setting, reduces morbidity among urban children with asthma.
- Trial name
- PAIR-UP (NCT01105754)
- Testing
- Multifaceted Prompting Intervention MPI
- Where
- United States
- Volunteers
- 638 people
- Sponsor
- University of Rochester
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.